Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

New Directions With PARP Inhibitors in Pancreatic Cancer

Listen to Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP, discuss emerging therapeutic strategies involving PARP inhibitors that are being investigated for the treatment of pancreatic cancer.
Eileen M. O'Reilly, MD
person default
Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP
Released: February 21, 2022

In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP,  discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

  • Current treatment landscape and testing in the United States vs the United Kingdom  
  • Testing for molecular subgroups beyond BRCAm
  • Using PARP inhibitors in earlier stages of the disease
  • Learning from other cancers, such as prostate, breast, and ovarian

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
AstraZeneca

Information on this Educational Activity

Faculty

Eileen M. O'Reilly, MD

Winthrop Rockefeller Chair in Medical Oncology
Section Head, 
Hepatopancreaticobiliary/Neuroendocriine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York

Eileen M. O’Reilly, MD, has disclosed that she has received funds for research support from Agios, Arcus, AstraZeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, and Yiviva and consulting fees from Adicet, Alnylam, AstraZeneca, Autem, Bayer, BeiGene, Berry Genomics, Celgene, Cend, CytomX, Eisai, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Lilly, Merck, Nerviano, QED, Rafael, Redhill, Servier, Silenseed, Sobi, Surface Oncology, Therabionics, Vector, and Yiviva.
Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP

Associate Director of Clinical Research
Reader
Department of GI Cancers
The Royal Marsden Hospital/ICR
Consultant Medical Oncologist, GI Cancers
London, United Kingdom

Naureen Starling, MD, FRCP, has disclosed that she has received consulting fees from Amgen, GSK, Lilly, MSD, Novartis, Pierre Fabre, and Servier.

Program Medium

This program has been made available online.

Related Content

Data from the CONKO-007 trial of chemoradiotherapy vs chemotherapy for locally advanced pancreatic cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 10, 2022

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for pancreatic and biliary tract cancers

Michael J. Pishvaian, MD, PhD Released: June 3, 2022

Experts highlight key studies being presented at the 2022 ASCO Annual Meeting in this commentary from Clinical Care Options (CCO)

Allison Betof Warner, MD, PhD John M. Burke, MD Shaji K. Kumar, MD Christopher H. Lieu, MD Stephen V. Liu, MD Joyce O'Shaughnessy, MD Zofia Piotrowska, MD, MHS Angeles Alvarez Secord, MD, MHSc Rachna Shroff, MD Hussein Tawbi, MD, PhD Eunice S. Wang, MD Released: June 1, 2022

From Clinical Care Options (CCO), downloadable PDF featuring key points from expert discussion on PARP inhibitors in treatment of pancreatic cancer

Eileen M. O'Reilly, MD person default Naureen Starling, BSc(Hons), MBBS, MD(Res), FRCP Released: May 3, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings